No, swollen lymph nodes (lymphadenopathy) are not listed as a recognised side effect in the UK regulatory data for GLP-1 receptor agonists
This story was reported from Los Angeles
EMA has just published recommendations to prioritize the distribution of GLP-1R agonists to high-risk patients and launch awareness campaigns to prevent off-label prescribing
Diabetes GLP-1s perform better but still leak demand: Diabetes-indicated GLP-1s show higher retention (24% at one year) and face fewer access hurdles due to broader coverage and disease framing, yet 76% of demand remains unmet
You have to provide them access to a registered dietitian, you have to provide them access to a gym membership, you have to provide them access to a fitness instructor or whatever network of services it is that you can provide to make sure that the change is in a lifestyle and not just in taking a medication once a week, he said
The Sidestep: Treat the process with the seriousness it deserves